Protocol No
MYTHIC-MYTX-011-01
Phase
I
Summary
This project is being done to determine the safety and tolerability, the best dose for future
development, as well as antitumor activity of a new antibody drug conjugate [ADC] called
MYTX-011.
Description
A Phase 1 Study of MYTX-011 in Subjects with NSCLC
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
ClinicalTrials.gov